Enliven Therapeutics: director Garland J. Scott exercised and sold 13,000 shares

What happened The filing reports that Garland J. Scott, an outside director, exercised options to acquire 13,000 shares at $15.47 on Oct 1, 2026, for $201,110 and sold 13,000 shares in an open-market transaction on Oct 1, 2026 at a weighted average price of $46.67 for $606,719. The filing also includes a derivative-related disposition of 13,000 shares reported at $0.00.

Key details

• Transaction date(s) and price(s): Oct 1, 2026 — exercised 13,000 shares at $15.47 (acquired); sold 13,000 shares at weighted average $46.67 (range $46.62 to $46.87 per footnote F1); derivative disposition 13,000 shares at $0.00.
• Shares owned after the transaction: not reported in the materials provided in this filing.
• Relevant footnotes: F1 notes the sale executed in multiple trades at prices from $46.62 to $46.87 and the weighted average sale price is reported; F2 states the option was originally for 59,372 shares and vests 1/36th on Feb 7, 2026 and each month thereafter, subject to continued service as an outside director.
• Filing date and timeliness: filed on Oct 5, 2026 covering the Oct 1, 2026 transactions; filed within the Form 4 two-business-day deadline.

Why it may matter The filing shows an option exercise followed by an immediate sale of the exercised shares (shares sold the same day, i.e., a cashless sequence reported in the filing). The filing does not show why the insider traded or why the company acted.